|
DNA immunisation with minimalistic expression constructs.
Moreno S, Lopez-Fuertes L, Vila-Coro AJ, Sack F, Smith CA, Konig SA, Wittig B, Schroff M, Juhls C, Junghans C, Timon M.
Vaccine. 2004 Apr 16;22(13-14):1709-16
Medline Abstract
Schistosoma mansoni miracidia transformed by particle bombardment infect Biomphalaria glabrata snails and develop into transgenic sporocysts
Heyers O, Walduck AK, Brindley PJ, Bleiss W, Lucius R, Dorbic T, Wittig B, Kalinna BH
Experimental Parasitology 2003 Oct 105;2:174-178
Medline Abstract
DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice.
L. López-Fuertes , E. Pérez-Jiménez , A.J. Vila-Coro , F. Sack , S. Moreno ,
S.A. Konig , C. Junghans , B. Wittig , M. Timón , M. Esteban
Vaccine 2002 Dec 13;21(3-4):247-57
Medline Abstract
Priming of immune responses to hepatitis B surface antigen with minimal DNA expression constructs modified with a nuclear localization signal peptide.
Schirmbeck R, Konig-Merediz SA, Riedl P, Kwissa M, Sack F, Schroff M, Junghans C, Reimann J, Wittig B.
J Mol Med 2001 Jun;79(5-6):343-50
Medline Abstract
A novel minimal-size vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA.
Schakowski F, Gorschluter M, Junghans C, Schroff M, Buttgereit P, Ziske C, Schottker B, Konig-Merediz SA, Sauerbruch T, Wittig B, Schmidt-Wolf IG.
Mol Ther 2001 May;3(5 Pt 1):793-800
Medline Abstract
Therapeutic Vaccination against Metastatic Carcinoma by Expression-Modulated and Immunomodified Autologous Tumor Cells: A First Clinical Phase I/II Trial.
Wittig B, Marten A, Dorbic T, Weineck S, Min H, Niemitz S, Trojaneck B, Flieger D, Kruopis S, Albers A, Loffel J, Neubauer A, Albers P, Muller S, Sauerbruch T, Bieber T, Huhn D, Schmidt-Wolf IG
Hum Gene Ther 2001 Feb;12(3):267-278
Medline Abstract
Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
Leutenegger CM, Boretti FS, Mislin CN, Flynn JN, Schroff M, Habel A, Junghans C, Koenig-Merediz SA, Sigrist B, Aubert A, Pedersen NC, Wittig B, Lutz H
J Virol 2000 Nov;74(22):10447-57
Medline Abstract
Cloning of an interferon regulatory factor 2 isoform with different regulatory ability.
Koenig-Merediz SA, Schmidt M, Hoppe GJ, Alfken J, Meraro D, Levi BZ, Neubauer A, Wittig B
Nucleic Acids Res 2000 Nov 1;28(21):4219-24
Medline Abstract
Expression of Interferon Regulatory Factor 4 in Chronic Myeloid Leukemia: Correlation With Response to Interferon Alfa Therapy.
Schmidt M, Hochhaus A, Koenig-Merediz SA, Brendel C, Proba J, Hoppe GJ, Wittig B, Ehninger G, Hehlmann R, Neubauer A
J Clin Oncol 2000 Oct 19;18(19):3331-3338
Medline Abstract
Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
Boretti FS, Leutenegger CM, Mislin C, Hofmann-Lehmann R, Konig S, Schroff M, Junghans C, Fehr D, Huettner SW, Habel A, Flynn JN, Aubert A, Pedersen NC, Wittig B, Lutz H
AIDS 2000 Aug 18;14(12):1749-57
Medline Abstract
Ballistic transfer of minimalistic immunologically defined expression constructs for IL4 and CTLA4 into the corneal epithelium in mice after orthotopic corneal allograft transplantation.
Koenig-Merediz SA, Zhang EP, Wittig B, Hoffmann F
Graefes Arch Clin Exp Ophthalmol 2000 Aug;238(8):701-7
Medline Abstract
Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.
Schmidt-Wolf I, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft H-G, Prang G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D
Br J Cancer 1999 Nov;81(6):1009-16
Medline Abstract
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study.
Möller P, Sun Y, Dorbic T, Alijagic S, Makki A, Jurgovsky K, Schroff M, Henz BM, Wittig B, Schadendorf D
Br J Cancer 1998 Jun 77:11 1907-16
Medline Abstract
Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study.
Sun Y, Jurgovsky K, Möller P, Alijagic S, Dorbic T, Georgieva J, Wittig B, Schadendorf D
Gene Ther 1998 Apr 5:4 481-90
Medline Abstract
Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias.
Schmidt M, Nagel S, Proba J, Thiede Ch, Ritter M, Waring JF, Rosenbauer F, Huhn D, Wittig B, Horak I, and Neubauer A
Blood 1998, 91, 22-29
Medline Abstract
Intratumoral adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) in a melanoma patient leading to regression of local tumor mass. A case report.
Möller P, Wittig B, Schadendorf D
Anticancer Res 1998 Mar-Apr 18:2B 1237-41
Medline Abstract
Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment.
Henze G, Borgmann A, von Stackelberg A, Baumgarten E, Uchanska-Ziegler B, Ziegler A, Wittig B
J Mol Med 1998 Mar 76:3-4 215-21
Medline Abstract
Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S, Trojaneck B, Lefterova P, Csipai M, Wagner E, Kircheis R, Neubauer A, Huhn D, Wittig B, Schmidt-Wolf IG
Gene Ther 1998 Jan 5:1 31-9
Medline Abstract
Nuclear application of antisense oligonucleotides by microinjection and ballistomagnetic transfer to identify G protein heterotrimers activating phospholipase C.
Kalkbrenner F, Dippel E, Schroff M, Wittig B, Schultz G
Methods Mol Biol 1997 83 203-16
Medline Abstract
P53 and induction of apoptosis as a target for anticancer therapy.
Neubauer A, Thiede C, Huhn D, Wittig B
Leukemia 1996 Jul 10 Suppl 3 S2-S4
Medline Abstract
Interleukin 7 trials for melanoma treatment [letter; comment]
Schadendorf D, Henz BM, Wittig B
Mol Med Today 1996 Apr 2:4 144-5
Medline Abstract
Interleukin-7, interleukin-12, and GM-CSF gene transfer in patients with metastatic melanoma.
Schadendorf D, Czarnetzki BM, Wittig B
J Mol Med 1995 Sep 73:9 473-7
Medline Abstract
Interleukin-7 gene transfer in patients with metastatic colon carcinoma, renal cell carcinoma, melanoma, or with lymphoma.
Schmidt-Wolf IG, Huhn D, Neubauer A, Wittig B
Hum Gene Ther 1994 Sep 5:9 1161-8
Medline Abstract
A strategy for the construction of double-stranded DNA microcircles with circumferences less than 50 bp.
Wolters M, Wittig B
Anticancer Drug Des 1990 Feb 5:1 111-20
Medline Abstract
Construction of a 42 base pair double stranded DNA microcircle.
Wolters M, Wittig B
Nucleic Acids Res 1989 Jul 11 17:13 5163-72
Medline Abstract |